Fulcrum Therapeutics, Inc. (FULC)
12.80
-1.00
(-7.25%)
USD |
NASDAQ |
Dec 11, 16:00
13.24
+0.44
(+3.44%)
Pre-Market: 09:13
Fulcrum Therapeutics Cash from Investing (Quarterly): 18.61M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Agios Pharmaceuticals, Inc. | 95.56M |
| Biogen, Inc. | -35.10M |
| CorMedix, Inc. | -291.32M |
| Apellis Pharmaceuticals, Inc. | -0.148M |
| NovaBay Pharmaceuticals, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.19M |
| Cash from Financing (Quarterly) | 0.064M |
| Free Cash Flow | -60.41M |
| Free Cash Flow Per Share (Quarterly) | -0.2281 |
| Free Cash Flow to Equity (Quarterly) | -13.72M |
| Free Cash Flow to Firm (Quarterly) | -14.28M |
| Free Cash Flow Yield | -7.82% |